

The next frontier in NSCLC diagnostics: Integrating emerging biomarkers into clinical practice

Wednesday, 26 March 2025, 11:00-12:00 CET,
Room N03, Hall 7, Level 7.3,
Paris Expo Porte de Versailles, Paris, France



Philip Jermann
Director Medical Affairs
EMEA at Thermo Fisher
Scientific



Natasha Leighl
Medical Oncologist,
Princess Margaret Cancer
Centre and University of
Toronto, Canada



Fernando Schmitt
Professor of Pathology,
Medical Faculty of Porto
University, Portugal

Agenda

Welcome and Introduction

Philip Jermann

Emerging biomarkers: shaping the future
of NSCLC testing and clinical integration

Natasha Leighl

Real-world insights into the analytical
performance of next generation sequencing
for HER2 mutation detection

Fernando Schmitt

Q&A and panel discussion

Philip Jermann

Closing remarks



Global Oncology
Diagnostics



Thermo Fisher
SCIENTIFIC